Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Multiple Sclerosis

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet Neurol.

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I

doi: 10.1016/

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Lancet Neurol.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D

doi: 10.1016/S1474-4422

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

J Neurol Sci.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W

doi: 10.1016/j.jns.2017.03.001.

Multiple Sclerosis

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany

Neurology.

Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C

doi: 10.1212/WNL.

Multiple Sclerosis

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

JAMA Neurol.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T, MSBase Study Group

doi: 10.1001/jamaneurol.

Multiple Sclerosis

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

Brain

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J

doi: 10.1093/brain/awy154.

Multiple Sclerosis

The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study

Pediatr Neurol.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J

doi: 10.1016/

Related content

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Vaccination Readiness in Multiple Sclerosis

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study